TGM2 and cranioectodermal dysplasia: The diagnosis of CeD is based on specific serological tests—such as anti-tissue transglutaminase (IgA-TG2), anti-deamidated gliadin peptide (IgG-DGP) or anti-endomysial antibodies (IgA-EmA)—and confirmed, histologically, by an enteropathy consisting of villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes observed in duodenal biopsies [1,2].